Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Drug-class evidence
9 pivotal trials of semaglutide, spanning Wegovy, Ozempic. 26,379 total participants across the published evidence base.
Semaglutide is a once-weekly GLP-1 receptor agonist marketed as Wegovy and Ozempic. The published evidence base spans the STEP weight-management program (semaglutide 2.4mg), the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Mean weight loss in obesity RCTs ranges from approximately 10% to 17%, and the drug class has demonstrated reductions in major adverse cardiovascular events in both diabetes and obesity populations.
Primary-endpoint percent body-weight change for the published semaglutide weight-management trials. Conducted on FDA-approved branded products only.
| Trial | NCT ID | Percent weight loss |
|---|---|---|
| STEP-4 · Wegovy | NCT03548987 | 17.4% |
| STEP-TEENS · Wegovy | NCT04102189 | 16.1% |
| STEP-3 · Wegovy | NCT03611582 | 16.0% |
| STEP-5 · Wegovy | NCT03693430 | 15.2% |
| STEP-1 · Wegovy | NCT03548935 | 14.9% |
| STEP-2 · Wegovy | NCT03552757 | 9.6% |
| Trial | Brand | Indication | Weight loss | A1C reduction | N · year |
|---|---|---|---|---|---|
| SELECT | Wegovy | Cardiovascular outcomes | — | — | 17,604 · 2023 |
| STEP-5 | Wegovy | Obesity / overweight | 15.2% | — | 304 · 2022 |
| STEP-TEENS | Wegovy | Obesity / overweight | 16.1% | — | 201 · 2022 |
| STEP-1 | Wegovy | Obesity / overweight | 14.9% | — | 1,961 · 2021 |
| STEP-2 | Wegovy | Obesity + type 2 diabetes | 9.6% | — | 1,210 · 2021 |
| STEP-3 | Wegovy | Obesity / overweight | 16.0% | — | 611 · 2021 |
| STEP-4 | Wegovy | Obesity / overweight | 17.4% | — | 803 · 2021 |
| SUSTAIN-1 | Ozempic | Type 2 diabetes | — | -1.55% | 388 · 2017 |
| SUSTAIN-6 | Ozempic | Cardiovascular outcomes | — | — | 3,297 · 2016 |
SELECT · NCT03574597 · 2023
Wegovy20% relative risk reduction in MACE on semaglutide 2.4mg vs placebo (HR 0.80, 95% CI 0.72-0.90)
STEP-5 · NCT03693430 · 2022
WegovyMean weight loss 15.2% on semaglutide 2.4mg vs 2.6% on placebo at 2 years
STEP-TEENS · NCT04102189 · 2022
WegovyMean BMI change -16.1% on semaglutide 2.4mg vs +0.6% on placebo in adolescents
STEP-1 · NCT03548935 · 2021
WegovyMean weight loss 14.9% on semaglutide 2.4mg vs 2.4% on placebo (estimated treatment difference -12.4 percentage points)
STEP-2 · NCT03552757 · 2021
WegovyMean weight loss 9.6% on semaglutide 2.4mg vs 3.4% on placebo in adults with type 2 diabetes
STEP-3 · NCT03611582 · 2021
WegovyMean weight loss 16.0% on semaglutide 2.4mg + intensive behavioral therapy vs 5.7% on placebo + IBT
STEP-4 · NCT03548987 · 2021
WegovyParticipants continuing semaglutide lost an additional 7.9%; those switched to placebo regained 6.9% (between-group difference -14.8 percentage points)
SUSTAIN-1 · NCT02054897 · 2017
OzempicHbA1c reduction 1.45% (semaglutide 0.5mg) and 1.55% (semaglutide 1.0mg) vs 0.02% on placebo
SUSTAIN-6 · NCT01720446 · 2016
Ozempic26% relative risk reduction in MACE on semaglutide vs placebo (HR 0.74, 95% CI 0.58-0.95)
Trials cited are for the FDA-approved branded products containing semaglutide. Compounded versions have not been studied in equivalent randomized controlled trials. GLP1Zoom does not provide medical advice; discuss treatment with your prescribing clinician. Full disclaimer.